Acceder

Publicaciones - HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL

Cargando...
Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12. PubMed PMID: 29330208; PubMed Central PMCID: PMC5896708.
AÑO: 2018; IF: 5.252
29330208
Gallego, J; Reig, O; Sastre, J; Garcia, I; Segura, A; Capdevila, J; Carmona-Bayonas, A; Sevilla, I; Alonso, T; Crespo, G; de La Cruz, G; Benavent, M. Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study. NEUROENDOCRINOLOGY. 2018; 106:226-226.
AÑO: 2018; IF: 5.135
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, Roldán V, Muñiz J, Raña-Míguez P, Ruiz-Ortiz M, Cequier Á, Bertomeu-Martínez V, Badimón L, Anguita M, Lip GYH, Marín F; FANTASIIA Investigators. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace. 2018 Sep 1;20(9):1435-1441. doi: 10.1093/europace/eux314. PubMed PMID: 29095971.
AÑO: 2018; IF: 6.1
29095971
Del Monte A, Arroyo AB, Andrés-Manzano MJ, García-Barberá N, Caleprico MS, Vicente V, Roldán V, González-Conejero R, Martínez C, Andrés V. miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. PLoS One. 2018 Jun 14;13(6):e0198932. doi: 10.1371/journal.pone.0198932. eCollection 2018. PubMed PMID: 29902229; PubMed Central PMCID: PMC6002112.
AÑO: 2018; IF: 2.776
29902229
Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. PLoS One. 2018 Sep 7;13(9):e0203392. doi: 10.1371/journal.pone.0203392. eCollection 2018. PubMed PMID: 30192814; PubMed Central PMCID: PMC6128544.
AÑO: 2018; IF: 2.776
30192814
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL